Literature DB >> 11509607

Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities.

P D Smith1, L E Smythies, M Mosteller-Barnum, D A Sibley, M W Russell, M Merger, M T Sellers, J M Orenstein, T Shimada, M F Graham, H Kubagawa.   

Abstract

The intestinal mucosa normally displays minimal inflammation despite the close proximity between mucosal macrophages and lumenal bacteria. Macrophages interact with bacteria and their products through CD14, a surface receptor involved in the response to LPS, and CD89, the receptor for IgA (FcalphaR). Here we show that resident macrophages isolated from normal human intestine lack CD14 and CD89. The absence of CD14 and CD89 was not due to the isolation procedure or mucosal cell products, but was evident at the transcriptional level, as the macrophages expressed neither CD14- nor CD89-specific mRNAs, but did express Toll-like receptor 2 and 4 transcripts. Consistent with their CD14(-) phenotype, lamina propria macrophages displayed markedly reduced LPS-induced cytokine production and LPS-enhanced phagocytosis. In addition, IgA-enhanced phagocytosis was sharply reduced in lamina propria macrophages. Thus, the absence of CD14 and CD89 on resident intestinal macrophages, due to down-regulated gene transcription, causes down-modulated LPS- and IgA-mediated functions and probably contributes to the low level of inflammation in normal human intestinal mucosa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509607     DOI: 10.4049/jimmunol.167.5.2651

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  97 in total

1.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 2.  Membrane TLR signaling mechanisms in the gastrointestinal tract during sepsis.

Authors:  B M Buchholz; A J Bauer
Journal:  Neurogastroenterol Motil       Date:  2010-03       Impact factor: 3.598

3.  Human primary gastric dendritic cells induce a Th1 response to H. pylori.

Authors:  D Bimczok; R H Clements; K B Waites; L Novak; D E Eckhoff; P J Mannon; P D Smith; L E Smythies
Journal:  Mucosal Immunol       Date:  2010-03-17       Impact factor: 7.313

4.  Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10.

Authors:  E C Ebert; V Mehta; K M Das
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 5.  Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2.

Authors:  E Cario
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

6.  Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients.

Authors:  Gundi Heuschen; Christine Leowardi; Ulf Hinz; Frank Autschbach; Andreas Stallmach; Christian Herfarth; Udo A Heuschen
Journal:  Int J Colorectal Dis       Date:  2006-06-13       Impact factor: 2.571

Review 7.  Layers of mutualism with commensal bacteria protect us from intestinal inflammation.

Authors:  C Mueller; A J Macpherson
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

8.  Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway.

Authors:  Susu M Zughaier; Yih-Ling Tzeng; Shanta M Zimmer; Anup Datta; Russell W Carlson; David S Stephens
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Dendritic cells transmit HIV-1 through human small intestinal mucosa.

Authors:  Ruizhong Shen; Lesley E Smythies; Ronald H Clements; Lea Novak; Phillip D Smith
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

Review 10.  Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases.

Authors:  Zejun Zhou; Miao Ding; Lei Huang; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2016-09-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.